These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 23509325)
1. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325 [TBL] [Abstract][Full Text] [Related]
2. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926 [TBL] [Abstract][Full Text] [Related]
3. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology. Zhu G Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507 [TBL] [Abstract][Full Text] [Related]
4. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. Kamashev D; Vitoux D; De Thé H J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541 [TBL] [Abstract][Full Text] [Related]
5. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343 [TBL] [Abstract][Full Text] [Related]
6. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation. Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106 [TBL] [Abstract][Full Text] [Related]
7. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980 [TBL] [Abstract][Full Text] [Related]
8. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Isakson P; Bjørås M; Bøe SO; Simonsen A Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048 [TBL] [Abstract][Full Text] [Related]
9. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Nasr R; de Thé H Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087 [TBL] [Abstract][Full Text] [Related]
10. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740 [TBL] [Abstract][Full Text] [Related]
11. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046 [TBL] [Abstract][Full Text] [Related]
12. Function of PML-RARA in Acute Promyelocytic Leukemia. Testa U; Pelosi E Adv Exp Med Biol; 2024; 1459():321-339. PubMed ID: 39017850 [TBL] [Abstract][Full Text] [Related]
13. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820 [TBL] [Abstract][Full Text] [Related]
14. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML. Ahn MJ; Nason-Burchenal K; Moasser MM; Dmitrovsky E Oncogene; 1995 Jun; 10(12):2307-14. PubMed ID: 7784078 [TBL] [Abstract][Full Text] [Related]
15. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Nasr R; Lallemand-Breitenbach V; Zhu J; Guillemin MC; de Thé H Clin Cancer Res; 2009 Oct; 15(20):6321-6. PubMed ID: 19808868 [TBL] [Abstract][Full Text] [Related]
16. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. Dos Santos GA; Kats L; Pandolfi PP J Exp Med; 2013 Dec; 210(13):2793-802. PubMed ID: 24344243 [TBL] [Abstract][Full Text] [Related]